This is an AMP page which is for mobile devices.

View Non AMP page

Twitter

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / DERM - Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples

DERM - Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples

August, 12 2025 06:43 PM Journey Medical Corporation

2025-08-12 18:43:21 ET

More on Journey Medical

Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript
Journey Medical Corporation (DERM) Q1 2025 Earnings Call Transcript
Journey Medical GAAP EPS of -$0.18 beats by $0.06, revenue of $13.1M beats by $1.05M
Journey Medical outlines Emrosi launch momentum and targets expanded payer access in 2025
Seeking Alpha’s Quant Rating on Journey Medical

For further details see:

Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples

Stock Information

Company Name:	Journey Medical Corporation
Stock Symbol:	DERM
Market:	NASDAQ
Website:	journeymedicalcorp.com

Get DERM Alerts

News, Short Squeeze, Breakout and More Instantly...

Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.